Answers are grounded in this paper and cite their sources.
Perampanel is a selective, noncompetitive AMPA receptor antagonist that has recently been approved for treating localization-related epilepsy. This article reviews the pharmacology, clinical development, efficacy, and safety/tolerability of perampanel.
No takes yet. Share an insight, caveat, or question.
Gregory L. Krauss (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: